What Can Be Detected in a Stool Sample?

A single stool sample can reveal infections, early signs of cancer, chronic inflammation, pancreatic disease, dietary patterns, drug residues, and even the composition of the trillions of microbes living in your gut. What most people think of as medical waste is actually one of the richest diagnostic specimens available, and advances in molecular testing have dramatically expanded what clinicians and researchers can pull from it. The range goes well beyond the familiar test for blood in the stool, though that remains one of the most important uses.

Bacteria, Viruses, and Parasites

The most common reason a doctor orders a stool test is to identify the cause of an acute gastrointestinal infection. Older methods relied on growing bacteria in culture dishes or examining samples under a microscope for parasites, but modern multiplex PCR panels can scan for a dozen or more pathogens in a single run. One study comparing these approaches found that multiplex PCR detected pathogens in about 30% of submitted samples, while conventional testing caught a pathogen in only 18% of the same samples. The PCR panel picked up norovirus in roughly 10% of samples, Campylobacter in 5%, Clostridium difficile in 4%, Giardia in 3%, and several other organisms at lower rates.¹

These panels typically cover the usual bacterial suspects like Salmonella, Shigella, and certain strains of E. coli, alongside viruses such as norovirus, rotavirus, and adenovirus, plus parasites like Cryptosporidium and Entamoeba histolytica. FDA-cleared syndromic panels report overall sensitivity between 80% and 100% for most targets, with specificity above 90%.² The speed matters clinically: results often come back the same day, which can change treatment decisions and infection-control measures in hospitals.

Viral shedding in stool can persist well after symptoms resolve, which is both a diagnostic opportunity and a public health concern. In children with acute gastroenteritis, norovirus was still detectable in stool at 28 days in about 70% of cases, compared to roughly half for rotavirus and only about 14% for adenovirus.³ This prolonged shedding is one reason norovirus spreads so efficiently through daycare centers and cruise ships.

Helicobacter pylori

Stool testing is not limited to infections that cause diarrhea. Helicobacter pylori, the bacterium responsible for most stomach ulcers and a major risk factor for gastric cancer, can be diagnosed through a stool antigen test without any need for endoscopy. A systematic review of 89 studies covering nearly 11,000 patients found that the stool antigen test had a mean sensitivity of 91% and specificity of 93% for detecting active H. pylori infection.⁴ Newer monoclonal antibody-based versions of the test perform even better, with pooled sensitivity around 94% and specificity around 97%.⁵

The stool antigen test is also used after treatment to confirm that the infection has been eradicated, typically four to eight weeks after finishing antibiotics. In that post-treatment setting, the monoclonal test retains high accuracy, with sensitivity and specificity both above 90%.⁵ For patients who want to avoid the breath test or an upper endoscopy, the stool test offers a genuinely reliable alternative.

Screening for Colorectal Cancer

Stool-based cancer screening has evolved through several generations of technology. The oldest approach, the guaiac-based fecal occult blood test, detects the chemical activity of hemoglobin in stool but reacts to any source of blood, including dietary red meat. The newer fecal immunochemical test (FIT) uses antibodies specific to human hemoglobin, which makes it both more sensitive and less prone to false positives from diet. A Cochrane systematic review found that for detecting colorectal cancer, FIT had a summary sensitivity of about 65% to 76% depending on the cutoff used, compared to roughly 39% for the older guaiac test.⁶ FIT is also more acceptable to patients because it requires only a single sample and no dietary restrictions beforehand.⁷

Beyond blood, stool samples can now be tested for altered DNA shed by cancerous or precancerous cells lining the colon. The multi-target stool DNA test (marketed as Cologuard in the United States) combines detection of methylated genes, a mutant form of the KRAS gene, and a hemoglobin measurement into a single assay.⁸ Stool DNA methylation testing is an active area of research, with several commercial tests targeting different gene panels and showing varying levels of sensitivity and specificity, some outperforming traditional occult blood tests for early-stage cancers.⁹ None of these stool tests replace colonoscopy for people who test positive, but they significantly lower the barrier to screening for those who might otherwise skip it entirely.

Inflammatory Markers and the IBD Question

If you have chronic abdominal pain, bloating, or diarrhea, one of the most useful things a stool test can do is help figure out whether the problem is inflammatory bowel disease (IBD, which includes Crohn’s disease and ulcerative colitis) or irritable bowel syndrome (IBS). The two can look similar on the surface, but the treatment and prognosis are very different. Fecal calprotectin, a protein released by white blood cells when they migrate to an inflamed intestinal lining, has become the go-to stool biomarker for making this distinction.

A systematic review pooling data from 17 studies with nearly 2,000 patients found that fecal calprotectin had a summary sensitivity of about 86% and specificity around 92% for distinguishing IBD from IBS in adults.¹⁰ An earlier review using a calprotectin cutoff of 50 micrograms per gram of stool reported even higher pooled accuracy, with sensitivity at 93% and specificity at 94%.¹¹ The practical upshot: a negative calprotectin result makes IBD very unlikely and can spare you from an invasive colonoscopy. A positive result, on the other hand, signals that further investigation is warranted. Calprotectin is also used to monitor disease activity in patients already diagnosed with IBD, tracking whether inflammation is flaring or responding to treatment.¹²

Pancreatic Function and Fat Absorption

The pancreas secretes enzymes that are essential for digesting food, and when it fails to produce enough of them, a condition called pancreatic exocrine insufficiency, the evidence shows up in stool. Fecal elastase-1 (FPE1) is a pancreatic enzyme that passes through the gut without being broken down, so its concentration in stool directly reflects how well the pancreas is functioning. Levels below 200 micrograms per gram of stool suggest moderate insufficiency, and levels below 100 indicate severe disease. One validation study of a newer automated assay found sensitivity of about 87% and specificity above 94% at the 100 microgram cutoff, with strong correlation to established methods.¹³ The test is commonly used to evaluate chronic pancreatitis, cystic fibrosis, and unexplained weight loss.

A related but distinct test measures fecal fat content. When fat is not properly digested and absorbed, it ends up in stool in excess, a condition called steatorrhea. The traditional gold standard involves collecting all stool over 72 hours and measuring total fat output, but a spot sample analyzed by infrared reflectance can serve as a reasonable screening tool, at least in patients with chronic pancreatic disease. In that population, fecal fat concentration correlated well with formal fat-balance studies, with sensitivity around 89% and specificity above 97% at a 9% fat concentration threshold.¹⁴ In patients with non-pancreatic digestive disorders, the correlation was much weaker, which means the spot test works best as a targeted investigation rather than a general screen.

Bile Acids and Chronic Diarrhea

Bile acid diarrhea is an underdiagnosed condition where excess bile acids reach the colon and trigger watery stools. In countries without access to the SeHCAT retention test (including the United States), measuring total fecal bile acids over a 48-hour collection has become the primary diagnostic method. A threshold of roughly 2,337 micromoles per 48 hours has been used as the gold standard cutoff.¹⁵

The clinical significance is substantial. In a large study of patients with chronic unexplained diarrhea, increased bile acid excretion was identified in about half of them. Among those patients, more than 70% reported improvement with bile acid sequestrant therapy, compared to only about a quarter of patients with normal bile acid levels. Patients with selectively elevated primary bile acids were roughly three times more likely to respond to treatment than those with a general increase in total bile acids.¹⁶ Fecal bile acid testing is not yet routine, but given how common bile acid diarrhea appears to be among people labeled with IBS-diarrhea, it deserves wider use.

Mapping the Gut Microbiome

Stool is the primary window into the gut microbiome for both researchers and a growing number of consumer testing companies. Two main sequencing approaches are used. The first targets a specific gene (16S ribosomal RNA) shared by all bacteria, which works like a barcode to identify which bacterial groups are present. The second, shotgun metagenomics, sequences all the DNA in a sample indiscriminately, capturing bacteria, viruses, fungi, and even fragments of the host’s own DNA.¹⁷

The two methods have meaningful trade-offs. Shotgun sequencing has greater power to detect less abundant organisms and can identify species rather than just broader groups, but it costs more and requires more complex analysis. A comparison study found that the targeted approach captures only part of the community revealed by shotgun sequencing, particularly missing rare taxa.¹⁸ For research purposes, the choice depends on the question being asked. For consumer microbiome kits, which typically use the cheaper targeted approach, the results should be interpreted with caution since they provide an incomplete picture.

Beyond just cataloging which microbes are present, stool can reveal what those microbes are producing. Short-chain fatty acids like butyrate, propionate, and acetate are major fermentation products of dietary fiber, generated at a rate of roughly 300 millimoles per day in the colon. Only about 10 millimoles per day actually end up being excreted, because most are absorbed and used by the body.¹⁹ Changes in these metabolites have been linked to conditions ranging from inflammatory bowel disease to metabolic syndrome, although translating metabolite profiles into clinical action is still in its early stages.

Gut transit time itself, how fast food moves through your system, leaves a measurable signature in the microbiome. A large-scale study using a blue dye tracking method found that transit time explained more of the variation in microbiome composition than either stool consistency or stool frequency, accounting for about 17% of the microbial community differences between fast and slow transit groups.²⁰ This matters because researchers studying the microbiome need to account for transit time, or they risk attributing microbial differences to a disease when they are really just seeing the effect of how quickly stool moves through.

Intestinal Permeability and Immune Markers

The health of the gut barrier, often discussed informally as “leaky gut,” can also be assessed through stool. Fecal zonulin, a protein involved in regulating the tight junctions between intestinal cells, has been explored as a noninvasive marker of intestinal permeability. Research in both adults and children suggests that fecal zonulin levels correlate with standard permeability tests and with body mass index, though the correlation is strongest in overweight and obese individuals.²¹ In pediatric inflammatory bowel disease, fecal zonulin has been investigated as a potential marker of disease activity alongside calprotectin.²² The science here is less mature than for calprotectin, but fecal zonulin testing is already offered by some specialty labs.

Stool also contains secretory IgA (SIgA), an antibody that serves as the gut’s first line of immune defense. SIgA works by binding to pathogens and toxins in the intestinal lumen and preventing them from reaching the gut wall, a process sometimes called immune exclusion. It also influences the composition of the microbiome and helps shuttle antigens to immune cells in the gut lining.²³ Measuring fecal SIgA can give a snapshot of mucosal immune activity, which is sometimes useful in evaluating immune deficiencies or chronic gut infections, though it has not become a routine clinical test.

Drug Residues and Environmental Contaminants

Stool is an important route of excretion for many drugs, and analyzing fecal concentrations of a medication or its metabolites can shed light on how the body processes it. Researchers have developed validated assays to measure fecal levels of drugs like ketamine and its metabolites across multiple biological matrices, including stool.²⁴ In the case of mesalazine, a drug widely used for ulcerative colitis, researchers measured fecal drug concentrations to see whether they could guide dosing. That particular study found that fecal drug levels did not differ between patients with active and quiescent disease, so it turned out not to be a useful monitoring tool for that medication, but the attempt illustrates the principle.²⁵

A different category of detection has gained attention recently: microplastics. Tiny plastic particles are now routinely found in human stool, reflecting widespread environmental exposure through food, water, and packaging. A pilot study analyzing stool for ten different plastic types found microplastic particles in every sample, with median concentrations up to 3.5 particles per gram in the 50 to 500 micrometer size range, and polyethylene was the most common polymer.²⁶ Another study found microplastics in 17 of 18 fecal samples, with polypropylene being the dominant type in that cohort, followed by polyethylene and polystyrene.²⁷ The health consequences of this exposure are still unclear, but stool analysis is the most straightforward way to quantify it.

Newborn Meconium Testing

A specialized form of stool analysis applies to newborns. Meconium, the dark, tar-like substance that makes up a baby’s first bowel movements, accumulates in the fetal intestine during pregnancy and begins forming around the second trimester. Because it builds up over months, meconium captures a long historical record of substances the fetus was exposed to in utero, including drugs of abuse, alcohol metabolites, and environmental toxins. It provides a window into the second and third trimesters of pregnancy, complementing other matrices like amniotic fluid (which reflects early pregnancy) and fetal hair (which covers only the third trimester).²⁸ Meconium testing is used in both clinical and forensic settings when prenatal drug exposure is suspected.

Ancient Stool and Archaeological DNA

Stool analysis extends beyond the living. Coprolites, preserved ancient fecal samples, have become a valuable tool in archaeology and paleogenomics. Metagenomic sequencing of coprolites excavated from a Japanese shell-mound site dating back 5,500 to 7,000 years revealed DNA from gut microbes, viruses, and food organisms, providing biological evidence for the dietary habits of Jomon-period people that aligned with previous archaeological findings from the same site.²⁹ Researchers have also applied integrative analysis to dog coprolites from pre-Columbian sites in North America, identifying DNA from fish, birds, frogs, and plants consumed by the animals, and by extension, revealing what was available and eaten in those communities.³⁰

On the population scale, wastewater analysis, which is essentially pooled stool testing for entire communities, has expanded rapidly since its use during the COVID-19 pandemic. Metagenomic analysis of wastewater now enables surveillance of antimicrobial resistance genes and pathogens across communities without needing to test individuals.³¹ This is one of the clearest examples of how the information embedded in stool has value far beyond any single patient’s diagnosis.

Why Sample Handling Matters

With all of this diagnostic potential, it is worth knowing that how a stool sample is collected and stored can affect the results. For microbiome studies in particular, room-temperature storage can allow certain bacteria, especially the Enterobacteriaceae family, to overgrow and distort the picture. Stabilizing buffers like PSP or RNAlater have been shown to preserve the original microbial diversity profile regardless of storage time or temperature.³² For most standard clinical tests like calprotectin, elastase, or occult blood, the kits include their own preservatives and the instructions are straightforward. One reassuring finding from storage studies: the differences between individual people’s stool microbiomes are far larger than the differences caused by any storage method, suggesting that even imperfect handling is unlikely to erase meaningful biological signals.³³ That said, following the collection instructions that come with your kit still matters, especially if you are doing a test where small quantitative differences are clinically meaningful, like fecal calprotectin levels used to track IBD flares.